1. BioTrinity April 2016
soloMER Biologics:
Next-generation therapeutics for the treatment of auto-inflammatory disease
Dr Caroline Barelle CEO

2. soloMERs – small, simpler, stable and more effective than antibodies
Elasmogen – proprietary soloMER technology
soloMERs – small, simpler, stable and more effective than antibodies
Pipeline
Initial products for treatment of auto-inflammatory eye disease
Expansion of opportunity into other anti-inflammatory conditions (IBD)
Focus on Orphan indication Uveitis with £ 3.5 B market opportunity
Comprehensive IP portfolio & FTO position
Patents - immunisation, libraries, humanization, re-formatting, products
Experienced Management and Science Team
Track record of successful delivery to the clinic and commercial exits
£2 M non-dilutive and £850 K dilutive cash raised
Looking to raise £5 M Series A funding
• •

3. soloMERs are different
VNARs are the smallest naturally occurring, binding domains
soloMERs are fully humanized, clinical candidate VNAR domains
Four loops in a single domain of approx 11 kDa
Extended loops up to 35 amino acid residues
Predisposed to bind cryptic epitopes
Pockets, grooves - eg enzymes and receptors
Novel and “druggable” small proteins
Small, stable, soluble and flexible formatting
Comprehensive IP advantage
Non-antibody domain avoiding complex antibody landscape
soloMERs bind cryptic epitopes
• •

4. Anti-inflammatory therapeutics market
Predicted to grow to over $90 billion by 2017 (CAGR 6% global, 9% in Asia)
Use of Corticosteroids limits sustained market growth
Severe side effects and 30% non-responders
Anti-inflammatory biologics make up 55% of market in 2014
Respiratory, arthritis, MS portfolios are 80% of drugs in development
Orphan disease such as Uveitis have only a few drugs in the clinic
Repositioning of existing drugs rather than bespoke or tailored therapies
Elasmogen is delivering market need by tailoring anti-inflammatory therapy through site-specific drug delivery
• •

5. Our pathway to ocular products
soloMER Generation
(high affinity, specificity and functionality)
PoC in vivo
ELN/21 demonstrates equivalent anti-inflammatory protection in a CIA mouse model
Anti-inflammatory
Site Specific Delivery
soloMERTM USPs
(small, stable, soluble)
Targeting Inflammatory Ocular Disease
• •

6. Primary indication - Uveitis
Unmet Clinical need
70% auto-immune disease (target population)
Current mainstay therapy are systemic corticosteroids
1/3 patients are unresponsive (target population)
Market Opportunity
Our target market 120,000 unresponsive patients globally
Orphan indication
Our projected global market is approximately £3 Bn (treatment cost of £25 k/patient/episode)
Characterised by a very rapid (few days) and debilitating inflammation of the uvea
• •

7. Efficacy of ELN/21 in a model of Uveitis
ELN/21 delivered systemically, demonstrates clinical efficacy in a murine model of IRBP-induced Uveitis
A: Untreated (severe)
B: Cyclosporin (mild)
C : ELN/21 (mild)
• •

8. Potency equal to Humira at only 9% of size
Site-specific delivery of soloMERs
In vitro PoC
In vivo delivery
Potency equal to Humira at only 9% of size
• •

9. Elasmogen’s pipeline
• •

10. The Management Team
Chris Jones, Chairman; brings 25 years leadership roles in VC and Fortune 500 companies and is currently Chairman of Mologic. Chris has raised over $40 M in funding was CEO of GlySure and CEO of Tensys Medical taking the company to trade sale.
Caroline Barelle, CEO; has a strong commercial, bio-partnering and biologics drug discovery/development background having led Teams at Wyeth and subsequently Pfizer in Global Bio- therapeutic Technologies. Prior to this she was Alliance and Programs Manager at Haptogen Ltd.
Tim Morley, Pre-clinical/Regulatory; has over 25 years’ experience in drug discovery, regulatory safety and development with both major Pharmaceutical and start-up companies. Currently he is senior director of Pre-Clinical Drug Discovery at Smith and Nephew. .
Andy Porter, CTO; was the founder of Haptogen Ltd, acquired in 2007, by Wyeth Inc. and has been on the Board of NovaBiotics Ltd since NovaBiotics currently has two products in Ph 2 clinical trials, a global licensing deal with Taro Inc and a City funding round by Woodford Investment Management.
• •

11. Candidate molecules in two inflammatory indications
Seeking Series A : £5 M
£5.0 M will deliver:
Candidate molecules in two inflammatory indications
ELN/21 - IND ready in auto-inflammatory eye disease
ELN/22 - pre-clinical PoC completed
An established world-class operational capability
Discovery and late stage pre-clinical development of soloMERs
Recruit a Clinical Development Director
Multiple platform deals capable of generating future revenue streams
License NDure and progress towards “first-in-man” studies
• •

12. Validated orphan drug target with a market worth £3 B
Take Home
Validated orphan drug target with a market worth £3 B
Broader market opportunities in auto-inflammatory disease achievable
Experienced management team and SAB
Strong IP & FTO position (Platform, Products)
Commercial Partners in place, milestones achieved
Multiple licensing and collaboration opportunities
• •